ENDPOINTS
12/07/2019 12:34
Just hours after J&J’s oncology team bragged about scoring a breakthrough therapy designation for their BCMA CAR-T drug, they pulled the wraps off the multiple myeloma data for JNJ-4528 that impressed the FDA. Following up on some attention-grabbing data initially presented by their Chinese development partners at Legend 2 years…